STORM Therapeutics appoints Dr John Haurum to the Board of Directors

27 June 2019, Cambridge, UK: STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the appointment of Dr John Haurum as an independent Non-Executive Director with immediate effect.

Dr Haurum has over 20 years’ experience in the international biotech industry. Previously John was Chief Executive Officer of F-star, a clinical-stage biopharmaceutical company pioneering the development of novel bispecific antibodies, with multiple strategic collaborations with AbbVie, Merck KGaA, Denali and Boehringer Ingelheim.

Commenting on today’s appointment, Dr Keith Blundy, CEO of STORM Therapeutics said: “STORM is progressing fast in its preclinical work with our multiple programmes to showcase the capabilities of our novel platform. On behalf of the Board of Directors, I would like to welcome John to STORM where his experience of developing both oncology platforms and clinical stage companies will be invaluable.”

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH